An occupational health clinic builds a reliable drug testing program by splitting the book of business into two lanes: a non-DOT lane, where instant point of care devices can screen on site under a CLIA Certificate of Waiver, and a DOT lane, where every urine or oral fluid specimen must go to an HHS-certified laboratory under 49 CFR Part 40, with no exceptions for point of collection or instant devices. Getting that split right, and documenting it consistently, is what lets a clinic scale multi-employer volume without stumbling on a DOT audit or a workers' compensation dispute.
This guide covers how to structure a point of care program for pre-employment, random, post-accident, and return to duty testing, when to route a specimen to a lab instead of reading it on site, what CLIA waiver status covers, chain of custody basics, inventory planning across employer panels, and what OSHA's post-incident testing guidance means for the clinic's role as a neutral collection site.
Why Occupational Health Clinics Need a Structured Point of Care Program
Occ health clinics sit between employers and their workforce, running pre-employment screens for new hires, random testing pulls for safety-sensitive positions, post-accident testing after a workplace injury, and return to duty testing before an employee comes back from a positive result or treatment program. Each employer client has its own drug panel, DOT status, and turnaround expectations, so the clinic is effectively running several testing programs in parallel out of one collection room.
A well-run point of care program lets the clinic deliver same-visit negative results for the large share of specimens that screen clean, while routing anything non-negative, anything DOT-regulated, and anything with a chain of custody requirement to a certified laboratory. Clinics that serve a broad employer base often stock from a hospital and clinic drug testing collection built around instant multi-panel cups, since those devices are what make same-day screening possible for the non-DOT majority of the book.
Point of Care Testing Versus Lab Send Out: When Each Applies
The decision of whether a specimen gets read on site or shipped to a lab is not optional for every category of test. It is set by the specimen type, the regulatory status of the employer program, and what happens if the result is non-negative.
| Factor | Point of care (instant device) | Laboratory send out |
|---|---|---|
| Typical use case | Non-DOT pre-employment, random, and return to duty screens where the employer accepts an on-site negative | All DOT-regulated urine and oral fluid specimens, and any non-DOT specimen that screens non-negative |
| Result turnaround | Minutes, read visually or with a reader at the point of collection | Typically one to a few business days, depending on the lab and confirmation testing needed |
| Regulatory basis | Runs under the clinic's CLIA Certificate of Waiver when using an FDA-cleared waived test | Required for DOT specimens under 49 CFR §40.210, which states that point of collection urine, point of collection oral fluid, and instant tests are not authorized for DOT testing |
| Confirmation step | A non-negative screen is presumptive only and must still go to a lab for confirmation | Lab performs both an initial screen and, for anything non-negative, a confirmatory method such as GC-MS or LC-MS/MS |
| Chain of custody | Optional but recommended for defensibility on non-DOT specimens | Mandatory, using a federal Custody and Control Form for DOT specimens |
In practice, most clinics run instant multi-panel drug testing cups as the front line for non-DOT employer panels, then hold a lab account in reserve for DOT collections and for any non-negative result that needs confirmation before it goes back to the employer or MRO.
Separating the DOT and Non-DOT Workflow
The single most important operational rule in an occ health clinic's testing program is keeping DOT and non-DOT specimens on separate paths from the moment a donor walks in. DOT testing covers safety-sensitive employees regulated by agencies such as the FMCSA, FAA, and FTA, and it follows the procedures set out in 49 CFR Part 40, the Department of Transportation's drug and alcohol testing rule, overseen by the agency's Office of Drug and Alcohol Policy and Compliance. Under that rule, only urine and oral fluid specimens screened and confirmed at HHS-certified laboratories are permitted, and point of collection devices, including instant cups and cards, are explicitly not authorized for DOT purposes.
That means a clinic collecting for a trucking company's DOT random pool, or building a DOT pre-employment drug screen program for a transportation client, needs a federal Custody and Control Form, a certified collector trained on DOT-specific procedures, and a courier or shipping relationship with an HHS-certified lab. None of that applies to the clinic's non-DOT employer clients, who can generally use an instant on-site device and accept a same-visit negative result, provided the clinic operates under a valid CLIA waiver for that device.
CLIA Waiver Context for Clinic Testing
Any clinic performing point of care drug tests needs to understand what its CLIA status actually authorizes. Under the Clinical Laboratory Improvement Amendments program, a facility that holds a CLIA Certificate of Waiver is permitted to perform only tests that CMS and the FDA have categorized as waived, meaning simple tests with a low risk of an incorrect result when performed according to the manufacturer's instructions. A Certificate of Waiver does not authorize moderate or high complexity testing, and it does not remove the requirement to follow the manufacturer's package insert exactly, including storage conditions, read times, and specimen handling.
This is why device selection matters for a multi-employer clinic. Stocking devices from a CLIA waived and FDA cleared cup collection keeps the clinic inside the scope of its waiver, while using an unwaived or forensic-only device for routine walk-in screening would push the clinic into moderate complexity territory it is not certified to perform.
Chain of Custody Basics
Chain of custody is mandatory for every DOT specimen and strongly recommended for any non-DOT specimen that could end up in a workers' compensation claim, a termination dispute, or litigation. At minimum, a defensible chain of custody means one collector handles the specimen from collection through sealing, the collector and donor sign the custody form, the specimen is sealed with tamper-evident tape in the donor's presence, and every custody transfer is logged with a signature and timestamp. Clinics that batch collection supplies for multiple employer contracts typically standardize on one specimen collection supply set so collectors are not switching custody form formats between donors.
Inventory Planning for Multi-Employer Panels
Because every employer client can specify a different drug panel, from a basic 5-panel to an extended panel that adds fentanyl or K2 screening for a construction or safety-sensitive client, inventory planning is one of the biggest operational headaches for a busy occ health clinic. A few practices keep stockouts and expired lots from becoming a recurring problem.
- Map each employer contract to its exact panel configuration before ordering, rather than assuming one universal panel covers every client.
- Keep a rolling par level for the two or three most common panel configurations, since a handful of panel types typically cover the majority of employer volume.
- Track lot numbers and expiration dates separately for each device type, since a waived point of care device that has expired is no longer within its cleared performance claims.
- Reserve a standing account with a certified laboratory for DOT specimens and non-negative confirmations, so a testing day never stalls waiting on a courier arrangement.
Clinics onboarding new employer clients, especially staffing agencies or general employers building a workplace drug testing program for the first time, benefit from a short intake conversation up front about panel choice, DOT status, and expected testing volume, since that conversation drives the entire inventory plan.
OSHA Post-Incident Testing Guidance
Post-accident testing is one of the most common referral sources into an occ health clinic, and it is also one of the more misunderstood areas of compliance. OSHA's injury and illness recordkeeping rule, 29 CFR 1904.35, requires employers to have a reasonable procedure for employees to report work-related injuries, and it prohibits an employer from discharging or in any manner discriminating against an employee for reporting an injury or illness. Employers sometimes read that provision as banning post-accident drug testing altogether, which is not accurate.
OSHA clarified its position directly in an October 2018 memorandum, stating that a safety incentive program or post-incident drug testing policy only violates 29 CFR 1904.35(b)(1)(iv) if the employer uses it to penalize an employee for reporting an injury rather than for the legitimate purpose of promoting workplace safety. The memo lists testing to evaluate an incident's root cause, random testing, and testing required under state workers' compensation law as permissible examples. The practical guidance for a clinic is to encourage employers to test everyone whose conduct could reasonably have contributed to an incident, not only the employee who reported it, keeping the policy on the safety side of the line rather than the retaliation side.
Frequently Asked Questions
Can an occupational health clinic use instant point of care tests for DOT-regulated employees?
No. Under 49 CFR §40.210, only urine and oral fluid specimens screened and confirmed at an HHS-certified laboratory are authorized for DOT testing, and point of collection or instant devices are not permitted for that population.
What does a CLIA Certificate of Waiver allow a clinic to do?
A Certificate of Waiver allows a clinic to perform only tests categorized as waived under CLIA, meaning simple, FDA-cleared tests performed exactly according to the manufacturer's instructions. It does not authorize moderate or high complexity testing.
Does OSHA prohibit post-accident drug testing?
No. OSHA's October 2018 memorandum on 29 CFR 1904.35(b)(1)(iv) clarifies that post-incident drug testing is not prohibited as long as it serves a legitimate safety purpose and is not used to penalize an employee specifically for reporting an injury.
How should a clinic handle a non-negative point of care screen?
A non-negative result from an instant device is presumptive only. The specimen, or a portion of it, should be sent to a certified laboratory for confirmation using a method such as GC-MS or LC-MS/MS before the result is treated as final.
Related reading
This article is for general informational purposes only and does not constitute legal, medical, or compliance advice. Point of care drug test devices produce a preliminary screening result, not a diagnosis of drug use or impairment. Any non-negative screening result must be confirmed by an appropriate laboratory method and reviewed by a qualified professional, such as a Medical Review Officer, before any employment or clinical decision is made. Clinics should confirm their own CLIA and DOT program requirements directly with CMS, HHS, and the Department of Transportation.
